Hospitalar 2026—the 31st edition of Brazil’s leading healthcare exhibition—concluded on May 22, 2026. The event marked a notable inflection point for digital chronic disease management vendors seeking regulatory alignment in Latin America, particularly those developing infrared sensing and AI-powered remote monitoring solutions. Stakeholders in medical device export, clinical-grade sensor manufacturing, and health tech compliance services should take note: this event signals early-stage institutional validation of dual-certification pathways (ISO 13485 + IEC 62304) under Brazil’s ANVISA pre-review framework—a development with tangible implications for market access strategy across the region.

Event Overview

The 31st Hospitalar exhibition took place in São Paulo and closed on May 22, 2026. At booth G-270d, Chinese digital health company Lecan Medical exhibited a suite of home-based remote patient monitoring devices designed for chronic disease management. These included an infrared temperature sensing module, a low-power edge sensing terminal, and an AI vision algorithm platform. According to publicly shared information, these components have undergone ANVISA pre-review and achieved verification against both ISO 13485 (quality management systems for medical devices) and IEC 62304 (software lifecycle processes for medical device software).

Industries Affected

Medical Device Exporters Targeting Latin America

Exporters engaging with public procurement channels in Brazil and neighboring countries may face heightened scrutiny on conformity assessment documentation. The dual-certification verification demonstrated at Hospitalar 2026 establishes a reference pathway—not a requirement—for devices falling under ANVISA’s Class II–III categories, especially those incorporating uncooled infrared sensors or night vision imaging functionality.

Sensor Module Manufacturers (Cooled/Uncooled IR)

Suppliers of infrared sensing hardware—including cooled and uncooled thermal sensors—may encounter increased demand for traceable compliance evidence tied to medical software integration. The verification referenced in the announcement specifically covers sensor modules embedded within regulated health monitoring systems, not standalone industrial IR components.

AI Vision Platform Providers for Clinical Use

Vendors offering computer vision algorithms intended for clinical decision support (e.g., gait analysis, sleep posture monitoring, or nocturnal event detection) now have a documented precedent for aligning their software development lifecycle with IEC 62304. This applies only where such algorithms are integrated into ANVISA-regulated devices—not as general-purpose software tools.

Regulatory & Certification Support Service Providers

Firms offering ANVISA registration support, ISO 13485 implementation consulting, or IEC 62304 gap assessments may see rising inquiries related to combined certification strategies. The case presented at Hospitalar 2026 illustrates how concurrent pursuit of both standards can streamline pre-market review timelines—provided system architecture clearly separates hardware, firmware, and algorithmic layers.

What Relevant Enterprises or Practitioners Should Focus On

Monitor Official Updates from ANVISA on Dual-Certification Recognition

ANVISA has not issued formal guidance endorsing ISO 13485 + IEC 62304 as a unified pathway. Current verification appears to be project-specific and pre-review in nature. Stakeholders should track whether ANVISA publishes updated technical notes or registration checklists referencing this combination.

Assess Whether Your Product Category Aligns with the Validated Use Cases

The verification cited applies specifically to infrared temperature modules, edge sensing terminals, and AI vision platforms deployed in remote chronic disease monitoring contexts. It does not extend to fire detection IR systems or general-purpose night vision gear unless those products are formally classified as medical devices under ANVISA Resolution RDC No. 185/2017.

Distinguish Between Regulatory Signal and Procurement Eligibility

Pre-review verification is not equivalent to registration approval or inclusion in Brazil’s SUS (Unified Health System) procurement lists. Companies should avoid conflating successful technical validation with automatic eligibility for public tenders, which require separate bidding compliance and local representation requirements.

Review Supply Chain Documentation for Traceability Across Software-Hardware Interfaces

Where sensors or AI modules are sourced from third parties, manufacturers must ensure contractual and technical documentation explicitly supports IEC 62304-compliant software integration—especially version control, hazard analysis records, and verification test reports linked to final device configuration.

Editorial Observation / Industry Perspective

Observably, this outcome reflects growing maturity in how non-Brazilian medtech firms approach regulatory strategy in Latin America—not as a one-off submission, but as an integrated quality and software lifecycle effort. Analysis shows the emphasis lies less on achieving a ‘first-to-market’ milestone and more on building repeatable, auditable processes that map onto ANVISA’s evolving expectations for digital health products. From an industry standpoint, it is better understood not as a finalized regulatory precedent, but as a signal that ANVISA is actively testing interoperable assessment models for complex, software-driven devices. Continued attention is warranted—not because the pathway is codified, but because its iterative application may inform future guidance.

This development underscores a broader shift: regulatory readiness in emerging markets is increasingly defined by cross-standard coherence rather than isolated certification. For stakeholders, the immediate value lies not in replicating Lecan’s exact submission, but in auditing whether internal development practices—particularly at the firmware-algorithm-hardware interface—support verifiable, segmented compliance evidence. That capability, rather than any single certification badge, is what enables scalable market entry.

Information Sources

Main source: Public exhibition summary and booth-level technical disclosures issued by Lecan Medical at Hospitalar 2026 (São Paulo, May 20–22, 2026). No additional regulatory documents, ANVISA notices, or third-party audit reports were cited or verified in the original announcement. Ongoing observation is recommended regarding whether ANVISA publishes formal recognition or procedural updates referencing this dual-certification verification.